*Submit your email address to receive conference udpates

BioTrinity 2008 Keynotes and Panel Discussions - April 15-16, 2008

The following key notes and panel discussions will take place at BioTrinity 2008, featuring pharma heavyweights as Bristol-Myers Squib, Shire and AstraZeneca and VC's and Investment Banks such as Sofinnova (France) and Orion Healthcare Equity Partners, and Cannacord Capital

Featuring further international participation from Ablynx (Belgium), SynCo BioPartners (Netherlands), La Jolla Pharmaceutical (USA), and BioProcess Technology Consultants (USA).

Tuesday 15 April 2008
09:05-9:25 Key deal: Strategic development of a sustainable medium-sized biopharmaceutical company: Commercialisation of TroVax and ProSavin
Presentation on one of the largest ever licensing deals for a UK biotech from the leading biopharmaceutical company to have been spun-out of the University of Oxford.
  • Peter Nolan, SVP Commercial Development, Oxford BioMedica
09:45-10:30 Panel Discussion: How to Realise Value in Biotech Partnering & Financing
  • Chair: Charles Macfarlane, Non-Executive Director, PharmaVentures Ltd and previously Executive Director Worldwide Alliances, Licensing & Acquisitions at Proctor & Gamble (Chair)
  • Shaun Grady, Vice President Deal Management, Strategic Planning and Business Development, AstraZeneca, UK
11:00-11:45 Panel Discussion: Financing Alternatives in a Challenging Economy: IPO, M&A and Other Non-dilutive Financing.
Introduced by Ted Agne, President, Communication Strategy Group
16:00-16:30 Key Notes on the Growth and Development of the Sector
Key notes review of the findings of the most extensive exercise benchmarking the growth and development of the Oxford BioCluster, and launch of an extensive report detailing every deal, drug and company playing a role in the resurgence. Download the Cluster Report Table of Contents
  • Kurt Laskow-Pooley MBA, Cluster Analyst and Business Development Manager, OBN  "OBN BioCluster Report - A Review of Key Findings and Launch"
Wednesday 16 April 2008
09:05-09:40 VC Panel Discussion: Creating Opportunities to Exit a Biotech Business Earlier



Key Notes and Panel Discussion from US, EU and Corporate Venturers who have invested in companies and alliances involving the UK's biotechnology and healthcare industry
  • Chair: David Mott - Investment Director, Oxford Capital Partners
  • Zina Affas - Principal, Orion Healthcare Equity Partners
  • Graziano Seghezzi - Partner (Life Sciences), Sofinnova Partners (France)
  • Richard Seabrook PhD, MBA - Head of Business Development, Technology Transfer, Wellcome Trust
  • Jeffrey B. Moore, DPhil, MBA - Vice President, MP Healthcare Venture Management, Inc.
09:45-10:00 The Deal Making Dance - Licensing, Partnering and Strategic Alliances
Key notes from one of the world's top 10 pharmaceutical company's European Licensing Director.
  • Lubor Gaal, Director, Licensing Europe, External Science Technology & Licensing, Bristol-Myers Squib
13:00-14:00 European GMP Biomanufacturing: Is Bigger More Beautiful





This discussion will feature several European biomanufacturers and will be chaired by an internationally reknowned expert, considering difference between US and European best practice in GMP Biomanufacturing.

PROJECT PARTNERS

Project Partner: Thames Valley Life Science Network Project Partner: BioSpectrumAsia Project Partner: PharmaLicensing
Project Partner: London Biotechnology Network With a high number of biotech and pharmaceutical companies based in the county, the Kent bioscience sector is proud of its success in discovery and innovation found in its larger businesses, which co-exist with fledgling bioscience companies such as those found at the Kent Science Park in Sittingbourne. Project Partner: Surrey Enterprise Hub
BioProcess UK Drug Discovery Today covers not only drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed - Supporting Partners to BioTrinity MedNous
The STIMUNTRAN project has received European Regional Development Funding through the INTERREG III B Community Initiative NEW ENO Interreg IIIB North West Europe BioSpectrum